We performed an in vivo comparative study of activity of three substances of the nitrosourea group produced in Russia. All substances demonstrated high antitumor activity against various solid and leukemic tumors. Aranosa significantly enhanced life duration in mice with leukemia (by 65-194%) and inhibited the growth of solid tumors (by 49-99.6%). Lisomustine and ormustine showed higher activity than aranose. Single administration of lisomustine increased life span of mice (by 22-114%) and resulted in cure of all animals in four models: lymphoblastic leukemia L-1210, lymphocytic leukemia P-388, Lewis lung carcinoma, and cervical cancer RShM-5. After ormustine treatment, full recovery was observed only in groups with lymphocytic leukemia P-388 and cervical cancer RShM-5. These findings attest to higher activity of lisomustine in the studied models.

2010-05-01·Eksperimental'naia i klinicheskaia farmakologiia

[Hematological toxicity of some combined chemotherapy schemes involving aranoza].

Article

作者: Pokrovskiĭ, V S ; Treshchalin, M I ; Bodiagin, D A ; Treshchalina, E M

Hematological toxicity of four combined chemotherapy schemes--TAr, TPAr, EPAr, and IPAr--involving aranose (Ar), cisplatin (P), etoposide (E), irinotecan (I), and topotecan (T) in therapeutic regimes has been studied on healthy mice in comparison to the treatment with Ar in a high therapeutic dose. It is established that Ar alone induces early leucopenia, mostly as a result of lymphocytopenia followed by the absolute and relative neutrophilia; the TAr treatment leads to a moderate neutropenia; whereas the ternary combinations cause a moderate lymphocytopenia. A relatively high hematological toxicity among the ternary combinations was observed for TPAr. The total number of erythrocytes and thrombocytes in the peripheral blood of mice under the action of Ar and all combinations remains on the control level. The inclusion of Ar into the indicated schemes neither modifies the spectrum of hematological toxicity nor increases its level. The observed changes in the peripheral blood were reversible and were not accompanied by any impairment in the state of mice. The obtained results allow the combinations involving P, E, I, T, and Ar to be considered as promising for further investigation.

2009-12-01·Bulletin of Experimental Biology and Medicine4区 · 医学

Efficiency and Tolerance of Aranose Combinations with Cisplatin and Gemcitabine in Experimental Lung Cancer

4区 · 医学

Article

作者: V. I. Romanenko ; V. S. Pokrovsky ; E. M. Treshalina ; N. A. Lesnaya

The efficiency of aranose combinations with gemcitabine and cisplatin was studied in experimental Lewis lung epidermoid carcinoma. Significant synergism of all the studied combinations and their satisfactory tolerance was demonstrated. The gemcitabine+cisplatin+aranose combination was significantly more effective than gemcitabine+cisplatin.

100 项与 Aranoza 相关的药物交易

登录后查看更多信息